Evaluation status available after sign-in
About the journal
Current Research in Pharmacology and Drug Discovery is an open-access journal published by Elsevier in Netherlands, publishing in english. It is listed in DOAJ according to the sources read. Declared publication charge: 3,280 USD. Declared review time at DOAJ: 18 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Elsevier
- ISSN
- 2590-2571
- Country
- Netherlands
- Languages
- english
- Access
- Open access
- Declared publication charge
- 3,280 USD
- Articles in DOAJ
- 232
- Declared review time
- 18 weeks
- Declared peer-review model
- other
Index listings
- DOAJ · 2021-02-13
- Indexing
- DOAJ
- APC
- 3,280 USD
- Declared review time (DOAJ)
- 18 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
232
Most recent article
8 months ago
Average review time (journal-declared via DOAJ)
18weeks
Works in OpenAlex
245
Last recorded publication year
2026
Reported by OpenAlex in 2 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core
h-index
33
i10-index
111
From OpenAlex open data (CC0).
Editorial & policy12
- Last DOAJ review date
- 2026-04-27
- Added to DOAJ
- 2021-02-13
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSSPMCPortico
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 85%
- ORCID iDs in current deposits
- 70%
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity3
- Alternate titles
- CRPHAR
- Source type
- journal
- NLM unique ID (PubMed)
- 9918300982506676
Classification2
Subjects (DOAJ)
Medicine: Therapeutics. Pharmacology
LCC codes
RM1-950
Subject areas
- Computational Drug Discovery Methods
- Computational Drug Discovery Methods
- SARS-CoV-2 and COVID-19 Research
- Diverse Scientific and Economic Studies
- Diverse Scientific and Economic Studies
- COVID-19 Clinical Research Studies
- Computational Drug Discovery Methods
- COVID-19 Clinical Research Studies
Show all subjects (75)
- COVID-19 Clinical Research Studies
- Pharmacogenetics and Drug Metabolism
- SARS-CoV-2 and COVID-19 Research
- Inflammatory Bowel Disease
- SARS-CoV-2 and COVID-19 Research
- Inflammatory Bowel Disease
- Ferroelectric and Negative Capacitance Devices
- Ferroelectric and Negative Capacitance Devices
- Inflammatory Bowel Disease
- Big Data and Digital Economy
- Big Data and Digital Economy
- Human auditory perception and evaluation
- Asthma and respiratory diseases
- Educational Robotics and Engineering
- Advanced Drug Delivery Systems
- Asthma and respiratory diseases
- Asthma and respiratory diseases
- Alzheimer's disease research and treatments
- Educational Robotics and Engineering
- Human auditory perception and evaluation
- Nanoparticle-Based Drug Delivery
- Flavonoids in Medical Research
- Drug Transport and Resistance Mechanisms
- Tryptophan and brain disorders
- Neurological Disorders and Treatments
- MicroRNA in disease regulation
- MicroRNA in disease regulation
- Tryptophan and brain disorders
- Pharmacogenetics and Drug Metabolism
- RNA Interference and Gene Delivery
- Pharmacogenetics and Drug Metabolism
- Receptor Mechanisms and Signaling
- Ocular Diseases and Behçet’s Syndrome
- Receptor Mechanisms and Signaling
- RNA Interference and Gene Delivery
- RNA Interference and Gene Delivery
- Adipose Tissue and Metabolism
- Adipose Tissue and Metabolism
- Cholinesterase and Neurodegenerative Diseases
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Drug Transport and Resistance Mechanisms
- Neuroinflammation and Neurodegeneration Mechanisms
- Drug-Induced Hepatotoxicity and Protection
- Receptor Mechanisms and Signaling
- MicroRNA in disease regulation
- Drug Transport and Resistance Mechanisms
- Natural Antidiabetic Agents Studies
- Liver physiology and pathology
- Neuroinflammation and Neurodegeneration Mechanisms
- Drug-Induced Hepatotoxicity and Protection
- Drug-Induced Hepatotoxicity and Protection
- Long-Term Effects of COVID-19
- Adipose Tissue and Metabolism
- Inhalation and Respiratory Drug Delivery
- Adipokines, Inflammation, and Metabolic Diseases
- Synthesis and biological activity
- Advanced biosensing and bioanalysis techniques
- Pharmacological Effects of Natural Compounds
- Long-Term Effects of COVID-19
- Advanced Drug Delivery Systems
- Adipokines, Inflammation, and Metabolic Diseases
- Drug Solubulity and Delivery Systems
- Pharmacological Effects of Natural Compounds
- Advanced biosensing and bioanalysis techniques
- Tuberculosis Research and Epidemiology
- Tuberculosis Research and Epidemiology
- Nanoparticle-Based Drug Delivery
Keywords (DOAJ)
- pharmacology
- drug discovery
- pharmacotherapy
- drug action
- pharmacogenetics
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
Loading community confirmations…
The journal's record in other sources:Web of Science MJLDOAJ